Overwhelming clinical and epidemiological studies have identified elevated plasma total homocysteine (Hcy) as new important risk factor for atherosclerotic vascular disease. But the relationship between outcome and hyperhomocysteinemia in patients with acute myocardial infarction (AMI) has been rarely reported. This study aimed to evaluate the association between hyperhomocysteinemia and short-term outcomes of patients with AMI. Eight hundred five patients were divided into high Hcy level group (group H: N 5 457) and low Hcy level group (group L: N 5 348) according to the plasma Hcy levels of 15 mmol/L. The comparisons were made between 2 groups in the following aspects: sex, hypertension, diabetes, hyperlipidemia, the time for symptom from onset to percutaneous coronary intervention, homoccyteine, creatine phosphokinase isoenzyme (creatine kinase myocardial band), and the incidence of 30-day adverse events. The incidences of heart failure, cardiac rupture, death, and the total adverse cardiovascular events were statistically significantly higher in group H than in group L. But the incidence of postoperative angina pectoris and reinfarction was similar between groups. The results of logistic regression showed that the incidence of 30-day adverse events was closely related to the age and the level of Hcy. An elevated plasma total Hcy level in patients with AMI experienced pemutaneous coronary intervention may be related to the short-term outcomes. An elevated high plasma Hcy level also seems to be an independent predictor of 30-day cardiovascular events in patients with AMI.
BACKGROUND
Coronary artery disease (CAD) is the leading cause of death and disability worldwide. Arteriosclerosis and its complications, such as heart attack and stroke, are the major causes of death in developed countries. It was believed that age, hyperlipidemia, hypertension, diabetes, and smoking are common risk factors for cardiovascular disease. 1 Although most of the patients with CAD have at least 1 of the cardiovascular risk factors, 20% of patients with CAD have no conventional risk factors. 2 The role of novel biomarkers including homocysteine (Hcy) in atherothrombotic vascular disease and prediction of risk of CAD is being increasingly recognized. [3] [4] [5] [6] Overwhelming clinical and epidemiological studies have identified elevated plasma Hcy as new important risk factor for atherosclerotic vascular disease. 7, 8 Hyperhomocysteinemia increases the risk of CAD by increased thrombosis, adverse effects on endothelial function, promoting thickening of the intima, and oxidative damage of low-density lipoprotein. 9 The hyperhomocysteinemia was reported in 40% of patients with vascular disease, associated with obstructive cardiovascular disease, 11, 12 with restenosis and major adverse cardiac events after coronary angioplasty, 13 and with all-cause mortality. 14, 15 Additionally, some studies showed hyperhomocysteinemia may have prognostic value in mortality of patients with CAD. 16 However, the relationship between outcome and hyperhomocysteinemia in patients with acute myocardial infarction (AMI) has been few reported. Here, we aimed to access the possible relationships between hyperhomocysteinaemia and 30-day adverse cardiovascular events in patients with AMI.
METHODS
A total of 813 consecutive patients with AMI successfully treated with primary percutaneous coronary intervention within 12 hours from the onset of chest pain were selected. To avoid other variables that could influence the plasma concentration of Hcy, we excluded patients with a history of folic acid or vitamin B complex deficiency, and renal insufficiency (creatinine $1.5 mg/dL). The study protocol was approved by the Ethics Committee of the Tangshan Affiliated Clinical Hospital of Hebei Medical University. From January 2009 to February 2011, among 813 patients with ST elevation myocardial infarction consecutively admitted to our Cardiac Care Unit (CCU), 805 patients were included in the study because 8 patients had no follow-up. AMI is diagnosed if the patient fulfills 2 of the following 3 standards: (1) chest pain continuing for .30 minutes, (2) dynamic evolution of typical ST-T appears in the electrocardiogram, and (3) dynamic increases in troponin I, troponin T, and CK isozyme levels to .2-fold higher than the normal upper limit. Primary percutaneous coronary intervention procedures were performed by an experienced team at a high-volume center with a 24-hour invasive service. Quantitative angiographic analysis of the percentage of minimal lumen diameter stenosis, the lesion length, and the reference lumen diameter were conducted using a digital edge-detection algorithm (DU-QUE System). 17 Multivessel disease was defined by stenoses of .50% in 2 major epicardial coronary arteries. A successful procedure was defined as infarcted artery stenosis ,30% associated with Thrombolysis in Myocardial Infarction (TIMI) grade 2 or 3 flow. Venous blood was collected after overnight fasting from all the patients to measure the levels of Hcy. The study patients were divided into 2 groups: a group with a high Hcy level (group H: N 5 457) and a group with a low Hcy level (group L: N 5 348) according to the plasma Hcy levels of 15 mmol/L. The following primary end points were evaluated within 30 days of AMI. The adverse events included angina pectoris (with ischemic electrocardiographic ST-T changes, and coronary angiography confirmed no in-stent thrombotic occlusion), reinfarction (with ischemic electrocardiographic ST-T changes, and coronary angiography confirmed in-stent acute and subacute thrombotic occlusion), heart failure (Killip class $II), cardiac rupture, and death. All surviving patients were evaluated by clinical interview or telephone as part of a prospective follow-up program.
Results were presented as mean 6 SD for continuous variables, and as percentages for categorical data. Groups were compared (all tests 2 sided) by unpaired t test. Frequencies were compared using x 2 test. A multivariate logistic regression model was used to test the association of statistically different baseline variables between 2 groups with the end point. The final model included age, diabetes, hyperlipidemia, multivessel disease, the peak levels of creatine kinase myocardial band enzyme, and the level of Hcy. Statistical analysis was performed using SPSS for Windows 16.0 software.
RESULTS
The incidences of adverse cardiovascular events were compared between groups ( Table 1 ). The incidences of heart failure (9.6% vs. 2.3%, P , 0.001), cardiac rupture (3.5% vs. 1.1%, P , 0.05), and death (7.9% vs. 2.3%, P , 0.001) were statistically significantly higher in group H than in group L, whereas the incidence of postoperative angina pectoris (6.1% vs. 4.6%, NS) and reinfarction (4.4% vs. 3.4%, NS) was similar between groups. And the total adverse cardiovascular events (22.8% vs. 11.8%, P , 0.001) were statistically higher in group H than in group L.
Baseline clinical characteristics are listed in Table 2 . Traditional coronary risk factors, including age, hypertension, diabetes mellitus, and hypercholesterolemia were compared between groups. The mean age was older in group H than that in group L (61 6 10 vs. 57 6 11%, P , 0.001). No significant differences in gender were observed between groups (85% vs. 82%, NS). Furthermore, the incidence of hypertension was similar between 2 groups (43% vs. 49%, NS). But the incidence of diabetes (29% vs. 20%, P 5 0.004) and hyperlipidemia (10% vs. 4%, P , 0.001) were higher in group L than that in group H. Systolic blood pressure, diastolic pressure, and heart rate on admission was similar between 2 groups. However, a laboratory investigation demonstrated that the peak levels of creatine kinase myocardial band enzyme were higher in group H than that in group L (181.61 6 123.02 U/L vs. 165.90 6 99.95 U/L, P , 0.001). No significant differences were found between groups in the time from the onset of symptoms to reperfusion. In group H, the incidence of multivessel diseases was higher than that in group L (68.5% vs. 56.4%, P , 0.001).
In a multivariate logistic regression model ( 
DISCUSSION
Hyperhomocysteinemia is believed to promote atherogenesis and atherothrombosis through several mechanisms. 18 Homocysteine metabolism generates reactive oxygen species that can directly injure the endothelium. Homocysteine has been shown to inhibit nitric oxide synthase activity, leading to endothelial dysfunction. Other proatherogenic mechanisms attributed to hyperhomocysteinemia include dysregulated methylation of proteins and DNA resulting in abnormal vascular smooth muscle cell proliferation, as well as increased lipid peroxidation. Data from observational studies examining the association between elevated Hcy levels and cardiovascular morbidity and mortality in the general population have been inconsistent. Boushey et al 19 estimated that 10% of general population CAD risk is attributed to Hcy. Nygard et al 16 found a strong association between elevated Hcy concentration and overall mortality in patients with CAD. Homocysteine was an independent risk factor for allcause mortality in the Physicians' Health Study. 20 Male physicians with the highest 5% of Hcy levels demonstrated a 5-year relative risk of 3.4 for AMI or death due to coronary disease compared with subjects with the lowest 90% of Hcy levels. Eftychiou et al 21 suggested that hyperhomocysteinemia is not only associated with CAD but also with acute MI and multivessel CAD. In patients with acute MI, elevated Hcy levels are associated with a higher risk of coronary events and death, independently of other risk factors and the extent of CAD. 22 A meta-analyses of observational data demonstrated a similar association. Wald et al 6 evaluated 20 prospective studies and concluded 23 and Finnish North Karelia project 24 failed to find any association between hyperhomocysteinemia and CAD. A meta-analysis demonstrated Hcy level was less strongly associated to ischemic heart disease and stroke in general population than has been reported. 25 In this study, we found the incidences of heart failure, cardiac rupture, death, and the total adverse cardiovascular events were statistically significantly higher in group H than in group L. But the incidence of postoperative angina pectoris and reinfarction was similar between groups. Furthermore, a strong association between plasma Hcy and the total adverse cardiovascular events was observed in our study.
STUDY LIMITATIONS
The results of this study suggest an elevated high plasma Hcy level may be an independent predictor of 30-day cardiovascular events in patients with AMI. However, the present data provide no insight regarding the associated pathogenic mechanisms. Another limitation is that the results of a single center study with a small sample size may be influenced by patient selection biases. In future studies, the short follow-up period should be extended to predict the patient's risk more thoroughly.
CONCLUSIONS
An elevated plasma total Hcy level in patients with AMI experienced pemutaneous coronary intervention may be related to the short-term outcomes. A high plasma Hcy level also seems to be an independent predictor of 30-day cardiovascular events in patients with AMI. 
